Sun Exposure

Strict sun avoidance and unchecked tanning are both wrong answers. Long-term cohort data show that people who avoid the sun die earlier — mostly from heart disease and internal cancers — while people who burn or accumulate severe skin damage die earlier from melanoma and accelerated aging. The optimum is short, frequent, sub-burning exposure to a lot of skin, with sunscreen reserved for longer outdoor stretches.

The traditional dermatological position has been "the safest sun is no sun," and it stands up well for one outcome: melanoma and non-melanoma skin cancer scale roughly with cumulative UV dose. But long-running European cohorts — and now multidimensional UV-exposure analyses inside the UK Biobank — point to strict avoidance being itself a measurable risk factor for all-cause, cardiovascular, and internal-cancer mortality. The shape that best fits the data looks roughly J-like: low exposure is bad, very high exposure is bad, and a non-burning middle is best. The caveat is that the mortality evidence is entirely observational, and the most rigorous recent synthesis judged it mixed and insufficient to justify changing sun-protection guidance — so the framing below is a defensible reading of confounded data, not a settled fact.

What the evidence actually supports

Strong:

Strict sun avoidance is associated with higher all-cause mortality in observational cohorts. The Melanoma in Southern Sweden (MISS) cohort followed 29,518 Swedish women for ~20 years; avoiders of sun exposure had roughly double the mortality of the highest-exposure group (HR 2.0, 95% CI 1.6–2.5), and those with moderate exposure a 40% higher rate (HR 1.4, 95% CI 1.1–1.7)^[1]^[2]. The signal is biologically plausible but "avoidance" was self-reported and correlates with indoor lifestyle, lower activity, and comorbidity, so reverse causation and confounding are live concerns.
Cumulative UV is the dominant driver of skin aging. Wrinkling, solar elastosis, lentigines, and the leathery photoaged phenotype come from UV-driven matrix-metalloproteinase (MMP-1, -3, -9) activation degrading dermal collagen — not from chronological aging^[3]^[4].
UVB-driven cutaneous vitamin D synthesis is the human default. Diet contributes a small fraction of typical vitamin D status; without sun or supplements, deficiency is the rule at temperate latitudes^[5].

Moderate:

The dose-response looks roughly J-shaped, but the evidence is mixed. Strict avoidance and sunburn-level overexposure both appear worse than a non-burning middle. Markers of cumulative excess UV track with mortality: in the NHANES I follow-up of 8,472 white participants (1971–1992), severe actinic skin damage carried ~45% higher all-cause mortality (HR 1.45, 95% CI 1.22–1.72) and moderate damage 20% higher (HR 1.20, 1.08–1.32) — though actinic damage also correlates with age, outdoor occupation, and smoking, so this is a marker, not clean evidence that "excess UV" raises mortality^[6]. The caveat that downgrades this from Strong: the leading 2025 systematic review (55 studies, mostly ecological, no RCTs) found the mortality evidence "too variable to provide a rationale for changes to sun protection guidance," with all included studies at some-to-very-high risk of bias^[7].
Low vitamin D is largely a marker of low UV exposure, not the causal agent. Randomised and genetic evidence converge here: in the 25,871-participant VITAL trial, 2000 IU/day vitamin D3 did not reduce total invasive cancer (HR 0.96, 95% CI 0.88–1.06) or major cardiovascular events, with only a non-significant signal for cancer mortality (HR 0.83, 0.67–1.02)^[8]. Non-linear Mendelian randomization in the UK Biobank (n=307,601) found an L-shaped relationship — genetically low 25(OH)D raised mortality only in the deficient range, with no benefit from raising already-adequate levels^[9]. This is why supplement trials are largely null while sun-exposure cohorts show benefit: sunlight likely acts through non-vitamin-D pathways (nitric oxide, circadian, immune) — a pill replaces only one of the things sun deprivation removes.
Steady exposure is melanoma-neutral; intermittent burning drives the risk. The foundational meta-analysis of 57 studies found intermittent sun exposure a clear risk factor (summary RR 1.61, 95% CI 1.31–1.99) while chronic/occupational exposure was not associated and if anything slightly inverse (RR 0.95, 0.87–1.04), with sunburn history a consistent risk factor^[10].
UVA-driven nitric-oxide release lowers blood pressure. Skin holds large stores of nitrogen-oxide species that UVA mobilises into bioactive nitric oxide; population blood pressure tracks with latitude and season, and a cross-sectional analysis of 342,457 dialysis patients across 2,178 US clinics found ambient UV inversely associated with pre-dialysis systolic blood pressure^[11]^[12]. The mechanism is genuine, but the reported effect (~ −12 mmHg in white patients) is large for an environmental signal, the design is cross-sectional with no individual UV dosimetry, and several authors hold relevant commercial ties (AOBiome, Relaxsol, Fresenius) — so residual confounding is the likeliest partial explanation.
UV exposure activates a real skin-brain axis. Keratinocytes synthesise CRH, POMC, β-endorphin, and serotonin locally on UV exposure, and UVB induces β-endorphin in human skin. The opioid-like analgesia, naloxone-precipitated withdrawal, and conditioned aversion that define "UV addiction," however, are murine findings; human relevance is inferred rather than demonstrated, and the human-focused syntheses are reviews, not outcome trials^[13]^[14].
Bright morning sun anchors the circadian clock. Daylight intensity at the eyes (via melanopsin-expressing retinal cells) suppresses morning melatonin and sets the evening melatonin rise. This is the single highest-leverage cue for sleep timing — see Circadian rhythms.

Weak / preliminary:

Non-classical UVB photoproducts (lumisterol, tachysterol) act through alternative nuclear receptors (AhR, LXR, ROR) and appear photoprotective and anti-inflammatory in mechanistic and cell-culture work. Whether this matters clinically — i.e., whether sun-derived vs. oral vitamin D differ in long-term outcomes — is unsettled.
Oral systemic photoprotectants — Polypodium leucotomos extract (PLE), astaxanthin, oral nicotinamide — show mechanistic and short-trial signal for reducing photoaging and actinic damage, but are not substitutes for sunscreen^[15].

Caution:

Tanning beds, solarium use, and any history of sunburn sharply elevate melanoma risk and should be treated as straightforwardly harmful.
Familial melanoma, dense dysplastic nevi, very pale skin (Fitzpatrick I/II), or immunosuppression: there is no known "safe" intentional UV dose. Vitamin D status should be managed via oral supplementation, not sun^[16].

The mortality J-curve

The evidence base on sun and mortality has shifted because the methodology improved. Early cohorts approximated lifetime UV exposure with proxies like birth year — which conflates UV with everything else that changed across the 20th century (indoor work, diet, smoking, screening intensity). The MISS cohort improved on that with structured sun-habit interviews. UK Biobank's Sun-BEEM index is a four-item exposure score (time outdoors, residential ambient UV, solarium use, sun-protection use); in 419,007 White-European participants it found a monotonic inverse dose-response for all-cause mortality (HR 0.89 for medium and 0.84 for high vs. low exposure) — not a J-curve — with no clear dose-response for skin-cancer mortality but rising keratinocyte cancers. It is a preprint that has not completed peer review, so treat it as preliminary^[17].

The picture across these analyses is consistent:

Outcome	Moderate, non-burning UV	Sunburn / chronic excess	Strict avoidance
All-cause mortality	Lower	Higher	Higher
Cardiovascular mortality	Lower	Mixed	Higher
Internal cancers	Lower	Mixed	Higher
Cutaneous melanoma	Neutral / slight protection (steady exposure)	Sharply higher	Lower
Non-melanoma skin cancer	Higher with cumulative dose	Sharply higher	Lower

Skin-cancer risk and mortality risk move in opposite directions, and for a population without high melanoma genetic risk the observational balance tilts toward moderate exposure being net-positive. That said, the most rigorous synthesis to date is more cautious: across 55 studies (overwhelmingly ecological, no RCTs) the 2025 NIHR systematic review found roughly as many analyses pointing to benefit as to harm, judged every included study at some-to-very-high risk of bias, and concluded the evidence is too variable to warrant changing sun-protection guidance^[18]. The table reflects the direction of the better cohorts, not a settled consensus.

Why sun-derived vitamin D is not the same as a pill

Cutaneous vitamin D synthesis is a photochemical cascade: UVB (~290–315 nm) opens the B-ring of 7-dehydrocholesterol in epidermal keratinocyte and fibroblast membranes, generating previtamin D3, which thermally isomerises to cholecalciferol over hours. The molecule is then released slowly to the bloodstream bound to vitamin-D-binding protein (DBP).

Three differences from oral D3 matter:

Sustained kinetics. Sun-derived D3 enters the circulation slowly and rides DBP, which (on a single-lab pharmacokinetic argument, not independently replicated at the outcome level) is proposed to give it 2–3× the effective serum half-life of an equivalent oral dose. Oral D3 is absorbed via the gut into chylomicrons and lipoproteins and clears in roughly a day.
No toxicity ceiling. Excess UVB photodegrades surplus previtamin D3 into lumisterol and tachysterol — sun cannot cause hypervitaminosis D. Oral D3, by contrast, can.
Local epidermal supply. Keratinocytes are poorly vascularised and don't reliably import DBP-bound systemic D from the bloodstream; they rely on their own UV-driven synthesis to drive antimicrobial-peptide production, differentiation, and DNA-repair signalling. Oral supplementation does not fully reach this compartment^[19].

Lumisterol and tachysterol, long dismissed as inert byproducts, are increasingly recognised as bioactive ligands for AhR, LXR, and ROR receptors with photoprotective and anti-inflammatory effects in skin. Whether this translates to differences in clinical outcomes between sun-derived and supplemented vitamin D is not yet established.

Practical implication. Maintain a steady serum 25(OH)D across the year. At higher latitudes (above about 50°N) endogenous synthesis is essentially zero from roughly October through March, so oral vitamin D3 across the winter is the standard fix — see Vitamin D. Do not try to "bank" D in summer by deliberate overexposure — the photodegradation fail-safe means extra burning yields extra skin damage, not extra D^[20].

Cardiovascular and metabolic effects independent of vitamin D

UVA is the longer-wavelength, less DNA-damaging part of the spectrum, and it does something distinct: it photolyses cutaneous nitrogen-oxide stores into bioactive nitric oxide (NO), which diffuses systemically and triggers arterial vasodilation. This is the most plausible mechanism behind the latitude and seasonal blood-pressure gradients seen in dozens of populations: BP peaks in winter and falls in summer roughly independently of temperature^[21].

The effect is substantial enough to be visible in a 342,457-patient hemodialysis cohort with daily clinic BP recordings: incident UV was inversely and linearly associated with pre-dialysis systolic blood pressure after adjustment for ambient temperature, age, sex, and BMI^[22].

UV exposure also tracks with lower LDL-cholesterol, lower CRP and IL-6, and (in animal models) suppression of high-fat-diet–induced obesity that oral vitamin D does not reproduce^[23]. The implication is that low vitamin D in obese, hypertensive populations is partly a biomarker of UV deprivation rather than the upstream cause of their metabolic disease — and giving them a pill replaces only one of the things they're missing.

Mood, sleep, and the skin-brain axis

UV-exposed keratinocytes locally synthesise corticotropin-releasing hormone (CRH) → proopiomelanocortin (POMC) → β-endorphin, α-MSH, and ACTH; the skin has its own functional analogue of the hypothalamic-pituitary-adrenal axis. The β-endorphin reaches the systemic circulation and binds μ-opioid receptors centrally — which is why frequent sun exposure produces measurable opioid-like analgesia and mood elevation, and why naloxone reliably triggers withdrawal in UV-habituated mice^[24]^[25].

The skin also generates serotonin from tryptophan independently of the central serotonin system. Cutaneous serotonin synthesis falls in winter, contributing to the seasonal-pattern depression (formerly SAD) signature^[26].

For sleep specifically: bright morning sunlight at the eyes is the highest-leverage circadian zeitgeber. The retinohypothalamic tract carries this signal to the suprachiasmatic nucleus, which sets the evening melatonin rise that allows sleep onset 14–16 hours later. The dose that matters is daytime brightness (10,000+ lux outdoors vs. 100–500 lux indoors), not UV per se — see Circadian rhythms.

What UV actually does to skin

The visible signs of "old skin" — coarse wrinkling, leathery texture, sagging, lentigines, telangiectasias — are mostly photoaging, not chronological aging. Compare sun-protected skin (e.g., the underside of an upper arm) with sun-exposed skin (the back of the same hand) in any 70-year-old: the difference is the cumulative UV history.

Mechanism. UV photons drive an immediate burst of reactive oxygen species in the epidermis and upper dermis. ROS activate MAP-kinase signalling, which upregulates the AP-1 and NF-κB transcription factors. Those in turn:

Massively upregulate MMP-1 (interstitial collagenase) — cleaves type I/III fibrillar collagen, the dermis's main load-bearing protein.
Upregulate MMP-3 (stromelysin-1) — breaks down proteoglycans and fibronectin, and activates other latent MMPs.
Upregulate MMP-9 (gelatinase B) — finishes off the fragmented collagen pieces.
Down-regulate fibroblast procollagen synthesis at the same time, producing a structural deficit^[27].

UV also covalently modifies the surviving collagen — irreversible carbonylation at proline, arginine, and lysine residues, which disrupts fibroblast adhesion and contractile function. The matrix doesn't just thin; it stops working.

UVA penetrates deeply into the dermis and is the dominant driver of these changes. UVB penetrates less but causes most of the direct DNA damage (cyclobutane pyrimidine dimers) and is the dominant driver of skin cancer.

UV is also immunosuppressive. UVB-induced DNA damage triggers systemic, antigen-specific T-cell-mediated immunosuppression. The clinical signature is stark: solid-organ transplant recipients, who are pharmacologically immunosuppressed, develop cutaneous squamous-cell carcinoma at 65–250× the background rate (and ~10× for basal-cell carcinoma) — direct evidence that immune surveillance normally restrains UV-driven skin cancer. This is a distinct hazard from photoaging and from the direct mutagenesis above, and it is part of why a healthy, exposure-naïve immune system tolerates incidental sun that an immunosuppressed one cannot.

Repair runs on a clock. Nucleotide excision repair (NER) — the system that excises UV-induced DNA lesions — is itself circadian, with peak capacity at specific phases of the 24-hour cycle. UV exposure at hours of low NER activity (deep evening, night — e.g., tanning beds) measurably amplifies the per-photon mutagenic load^[28]. Solar UV during normal daytime hours hits the body when DNA repair is most active.

Skin type changes everything

The Fitzpatrick scale tracks the eumelanin / pheomelanin balance. Lighter skin (Types I–III) is heavier in pheomelanin, which is a pro-oxidant under UV and amplifies free-radical damage. Darker skin (Types IV–VI) is heavier in eumelanin, a broad-spectrum filter and antioxidant.

Two practical numbers:

Innate SPF. Type I/II skin has an intrinsic SPF of about 3.3. Type V/VI skin has roughly 13.4. Eumelanin functions as built-in sunscreen.
Vitamin D synthesis time. A Fitzpatrick V/VI individual needs roughly 5–10× the UVB exposure of a Type II individual to make the same amount of vitamin D. Blanket sun-avoidance guidelines apply this 10× penalty without compensating with stronger oral repletion advice — which is part of why severe vitamin D deficiency is endemic in dark-skinned populations at temperate latitudes^[29].

The 2024 Australian/NZ revised position statement formalises this with three risk groups^[30]:

Very high skin-cancer risk — Fitzpatrick I/II, immunosuppression, melanoma history, dense dysplastic nevi. Year-round photoprotection; manage vitamin D with supplements.
High vitamin-D-deficiency risk, low skin-cancer risk — Fitzpatrick V/VI. Routine daily sunscreen during ordinary outdoor activity is discouraged; deliberate brief unprotected exposure to maintain vitamin D status is appropriate.
Intermediate — most of the population. Sub-erythemal exposure during incidental outdoor activity for systemic benefit; sunscreen for longer outdoor stretches and high UV index.

Practical guidance

Aim for micro-doses, not "tans"

The conversion of 7-dehydrocholesterol to previtamin D3 saturates quickly. Past that plateau, additional UV adds skin damage without adding vitamin D. The biologically efficient form is brief exposures of a lot of skin, repeated, not long exposures of small areas^[31].

A reasonable rule of thumb, for an intermediate skin type at midday with arms and legs uncovered:

UV index	Approximate exposure for vitamin D
1–2 (low)	Synthesis is slow; sunscreen rarely needed
3–5 (moderate)	15–20 min
6–7 (high)	10–15 min
8–10 (very high)	5–7 min
11+ (extreme)	< 5 min; high erythema risk, avoid direct mid-sun

These are population approximations from exposure modelling, not titratable prescriptions: real dose varies widely with body-surface-area exposed, age (cutaneous 7-DHC declines over the years), and skin type, and the modellers' own conclusion is that precise self-titration is impractical. Spread exposure across the week; do not "stack" it. Time between sessions is what lets nucleotide excision repair clear UV-induced DNA lesions before they accumulate.

Protect when exposure exceeds the synthesis dose

Once you're past the brief vitamin-D / NO window — long beach days, alpine hiking, sustained outdoor work — the calculation flips and the goal is photoprotection.

Broad-spectrum sunscreen (UVA + UVB). SPF 30–50 is sufficient for most skin types; SPF 50+ for Fitzpatrick I/II or with melanoma history. Older trials using SPF~16 found no effect on vitamin D status, but the 2025 Sun-D RCT found that daily SPF50+ use modestly lowered 25(OH)D (between-group −5.2 nmol/L) and raised deficiency prevalence (45.7% vs 36.9%), so regular high-SPF users may need supplementation^[32].
Hat, long sleeves, UV-blocking sunglasses. UV-driven cataracts, macular degeneration, and pterygium are real and largely preventable.
Avoid sunburn. This is the single most useful bright line. Burning is what tracks with melanoma risk; sub-erythemal exposure largely does not.
No tanning beds, ever. Their UV profile is not the daytime spectrum, exposure is at hours of low NER activity, and the risk-benefit balance is straightforwardly negative.

Oral systemic photoprotection — useful but adjunctive

A small, mechanistically coherent literature supports oral Polypodium leucotomos extract (PLE), astaxanthin, and oral nicotinamide as adjunct photoprotectants. PLE preserves cutaneous vitamin D receptor levels under oxidative stress via NRF2; nicotinamide supports the ATP-intensive NER repair process. The strongest datapoint is the ONTRAC trial (386 patients with prior non-melanoma skin cancers): 500 mg nicotinamide twice daily cut new non-melanoma skin cancers by 23% (95% CI 4–38) over a year^[33]^[34]. That is a modest effect in high-risk patients only and should not be generalised to healthy adults; these are useful additions for high-exposure days, not substitutes for sunscreen or for not burning.

Cautions and contraindications

Personal or strong family history of melanoma, dense dysplastic nevi, prior skin cancer, immunosuppression, photosensitising medications (some antibiotics, retinoids, amiodarone, NSAIDs, etc.): treat sun primarily as a hazard. Get a yearly dermatology check; manage vitamin D with supplements.
Pregnancy: moderate, non-burning sun is fine and relevant for vitamin D status. Avoid melasma triggers — Fitzpatrick III–V skin pigments aggressively under sun + hormones.
Eye health: the lens absorbs most UVB; chronic UVA exposure is the macular-degeneration and cataract risk. Real UV-blocking sunglasses are cheap and worth wearing on bright days.
Children: their thinner stratum corneum and higher remaining lifetime dose make burn-prevention the dominant priority; sub-erythemal play in the sun is fine and useful for vitamin D.

What's overrated

"Sunscreen causes vitamin D deficiency." Overstated, but no longer dismissible: daily SPF50+ use does modestly lower 25(OH)D (Sun-D RCT, −5.2 nmol/L), so it is a small real effect rather than a wholesale cause. Most population deficiency is still from indoor lifestyles and high latitude, not from sunscreen — regular high-SPF users simply have one more reason to keep oral D3 topped up.
Tanning as a longevity strategy. Tans are visible UV damage; they are not the source of the cardiovascular and mood benefits of sun, which appear at sub-erythemal doses long before tanning.
"You can store vitamin D in summer for winter." The half-life of 25(OH)D is several weeks; a high-latitude summer cannot cover a high-latitude winter. Use oral D3 across the dark months — see Vitamin D.
Oral D as a full substitute for sun. It restores systemic 25(OH)D but doesn't reproduce UVA-driven nitric oxide, the skin-brain axis, daytime circadian entrainment, or the local epidermal vitamin D supply. Useful, necessary at temperate latitudes — but not a complete replacement. No trial has yet pitted sun against equivalent oral D3 on a hard endpoint; the Australian SEDS Study, randomising enhanced-sun-exposure advice against vitamin D doses with immune and cardiometabolic outcomes, is the trial positioned to actually test this — so the question remains genuinely open.